{'fraction_non_alphanumeric': 0.02063273727647868, 'fraction_numerical': 0.002751031636863824, 'mean_word_length': 5.016528925619835, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adalimumab in the Treatment of Uveitis in Juvenile Idiopathic Arthritis.

Uveitis encompasses a collection of ocular diseases that are characterized by intraocular inflammation and categorized according to the anatomical location of the inflammation in the eye. In the United States, uveitis is estimated to be the fifth or sixth leading cause of blindness and affects a broad range of age groups, including children. As such, there is the potential for more years lost because of visual disability than from age-related ocular diseases that affect people much later in life.1,2 Juvenile idiopathic arthritis (JIA)–associated uveitis is typically a chronic bilateral anterior uveitis and is among the most common forms of . . .